Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Evaxion Biotech ( (EVAX) ) has provided an update.
On October 31, 2025, Evaxion A/S announced it will provide a business update and report its third quarter 2025 financial results on November 6, 2025. The company will host a conference call and webcast to present the update and results, which will be open to the public. This announcement is part of Evaxion’s ongoing efforts to engage with stakeholders and provide transparency about its financial health and strategic direction.
The most recent analyst rating on (EVAX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
Evaxion Biotech’s overall score is driven by strong technical indicators and positive developments from the earnings call, including R&D progress and financial stability. However, financial performance remains a concern due to ongoing losses and reliance on debt, impacting the valuation negatively.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion A/S is a clinical-stage TechBio company based in Denmark, specializing in the development of AI-Immunology™ powered vaccines. The company leverages its proprietary AI platform to create novel immunotherapies for cancer, bacterial diseases, and viral infections, with a focus on personalized vaccines and addressing high unmet medical needs.
Average Trading Volume: 1,586,483
Technical Sentiment Signal: Hold
Current Market Cap: $36.38M
See more insights into EVAX stock on TipRanks’ Stock Analysis page.